Clinical Trial

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase II study of camrelizumab combined with SOX regimen in subjects with resectable locally advanced gastric cancer. The patients will receive camrelizumab ,S-1 and oxaliplatin given every 3 weeks for 3 cycles as neoadjuvant therapy. After the surgery, adjuvant therapy which includes camrelizumab and SOX regimen will begin.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-11-01; most recent amendment 2023-09-26.
Trial Details
NCT Number NCT05602935
Lead Sponsor The Second Affiliated Hospital of Fujian Medical University
Conditions Stomach Neoplasms, Digestive System Neoplasms, Neoplasms, Digestive System Diseases, Stomach Diseases, Neoplasms by Site
Enrollment 29 participants
Start Date 2020-09-16
Primary Completion 2022-03-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-09-28